BioSpace News Archive

Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication

Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments

Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease will be highlighted in an oral presentation

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights on Thursday, March 18, 2021 at 8:30 a.m. ET.

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences: 33 rd Annual Roth Conference being held March 15-17, 2021.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor,

Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. During a conference call at 9 a.m. ET on April 29, 2021, company executives will review financial results and address inquiries from investors and analysts.

MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 – – Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various Patient Subsets and Dosing Durability – – Key Appointments Made to Executive Team in Preparation for Commercial Execution

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its fourth quarter and full year 2020 financial results will be reported on Thursday, March 18, 2021 before the open of the financial markets.

Mevion Medical Systems announced that it has signed a partnership agreement with Children’s Hospital of Fudan University in Shanghai and Shanghai Fosun Healthcare Co., Ltd. to establish the first pediatric proton therapy center in China.